Open the filing on EDGARCONMED Corporation Announces Third Quarter 2025 Financial Results
Largo, Florida, November 5, 2025 - CONMED Corporation (NYSE: CNMD) today announced financial results for the third quarter ended September 30, 2025.
Third Quarter 2025 Highlights
- Sales of $337.9 million increased 6.7% year-over-year as reported and 6.3% in constant currency.
- Domestic revenue increased 5.9% year-over-year.
- International revenue increased 7.8% year-over-year as reported and 6.8% in constant currency.
- Diluted net earnings per share (GAAP) were $0.09, compared to diluted net earnings per share (GAAP) of $1.57 in the third quarter of 2024.
- Adjusted diluted net earnings per share were $1.08, compared to adjusted diluted net earnings per share of $1.05 in the third quarter of 2024.
- Subsequent to quarter end, the Board of Directors authorized a $150.0 million share repurchase program and suspended the quarterly cash dividend; the Company anticipates repurchasing at least $25.0 million in shares annually beginning in 2026.
"We are pleased with our third quarter performance, which reflects continued progress in strengthening our supply chain and strong execution across our core growth platforms,” commented Patrick J. Beyer, CONMED’s President and Chief Executive Officer. “We are building on this momentum in the fourth quarter and beyond, supported by our portfolio of best-in-class clinical solutions, operational discipline, and commitment to innovation.”
2025 Outlook
Based on current foreign currency exchange rates, the Company continues to expect revenue currency headwinds to be immaterial. As a result of the Company’s foreign currency expectations and its third quarter performance, full-year reported revenue is now expected to be between $1.365 billion and $1.372 billion, compared to the prior guidance range of between $1.356 billion and $1.378 billion.
The Company now expects full-year adjusted diluted net earnings per share in the range of $4.48 to $4.53, with foreign currency estimated to be a headwind of approximately 10 cents. This is compared to its prior range of $4.40 to $4.55, with foreign currency then estimated to be a headwind of approximately 10 cents.
This updated guidance includes the effects of recent tariff announcements, which the Company estimates would result in a negative impact to EPS of approximately $0.07 in the fourth quarter of 2025.
Share Repurchase Authorization and Suspension of Dividend Payments
Effective October 31, 2025, CONMED’s Board of Directors authorized a $150.0 million share repurchase program (the “Modified Program”), which modified its prior $200.0 million share repurchase program (the “Prior Program”), under which $37.4 million had remained available for repurchases prior to the establishment of the Modified Program. With the decision to extend the share repurchase program, the Board of Directors suspended the Company’s quarterly cash dividend. The Company expects to repurchase at least $25.0 million in shares annually beginning in 2026.
Supplemental Financial Disclosures
A reconciliation of reported diluted net earnings per share to adjusted diluted net earnings per share, a non-GAAP financial measure, appears below.
Information reconciling forward-looking adjusted diluted net earnings per share to the comparable GAAP financial measures is unavailable to the company without unreasonable effort, as discussed below.
Conference Call
The Company’s management will host a conference call today at 4:30 p.m. ET to discuss its third quarter 2025 results.
To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode.
This conference call will also be webcast and can be accessed from the “Investors” section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
| Three Months Ended | Nine Months Ended |
|---|
| September 30, | September 30, |
|---|
| 2025 | 2024 | 2025 | 2024 |
|---|
| Consolidated Condensed Statements of Income |
| (in thousands except per share amounts, unaudited) |
| Net sales | $337,926 | | $316,701 | | $1,001,526 | | $961,071 | |
| Cost of sales | 171,807 | | 137,706 | | 469,336 | | 426,383 | |
| Gross profit | 166,119 | | 178,995 | | 532,190 | | 534,688 | |
| % of sales | 49.2% | | 56.5% | | 53.1% | | 55.6% | |
| Selling & administrative expense | 140,339 | | 99,730 | | 425,207 | | 345,611 | |
| Research & development expense | 13,901 | | 13,558 | | 40,985 | | 41,250 | |
| Income from operations | 11,879 | | 65,707 | | 65,998 | | 147,827 | |
| % of sales | 3.5% | | 20.7% | | 6.6% | | 15.4% | |
| Interest expense | 7,606 | | 9,252 | | 23,716 | | 28,440 | |
| Other expense | - | | - | | 418 | | - | |
| Income before income taxes | 4,273 | | 56,455 | | 41,864 | | 119,387 | |
| Provision for income taxes | 1,414 | | 7,471 | | 11,548 | | 20,719 | |
| Net income | $2,859 | | $48,984 | | $30,316 | | $98,668 | |
| Basic EPS | $0.09 | | $1.59 | | $0.98 | | $3.20 | |
| Diluted EPS | 0.09 | | 1.57 | | 0.97 | | 3.17 | |
| Basic shares | 30,955 | | 30,856 | | 31,027 | | 30,815 | |
| Diluted shares | 31,050 | | 31,112 | | 31,145 | | 31,148 | |
| Three Months Ended September 30, |
|---|
| | | % Change |
|---|
| | | | | | Domestic | International |
|---|
| 2025 | 2024 | As Reported | Impact of Foreign Currency | Constant Currency | As Reported | As Reported | Impact of Foreign Currency | Constant Currency |
|---|
| Sales Summary |
| (in millions, unaudited) |
| Orthopedic Surgery | $138.2 | | $130.5 | | 5.9% | -0.6% | 5.3% | 5.5% | 6.1% | -0.9% | 5.2% |
| General Surgery | 199.7 | | 186.2 | | 7.3% | -0.4% | 6.9% | 6.0% | 10.4% | -1.2% | 9.2% |
| $337.9 | | $316.7 | | 6.7% | -0.4% | 6.3% | 5.9% | 7.8% | -1.0% | 6.8% |
| Single-use Products | $289.2 | | $270.8 | | 6.8% | -0.5% | 6.3% | 4.7% | 9.9% | -1.1% | 8.8% |
| Capital Products | 48.7 | | 45.9 | | 6.3% | -0.3% | 6.0% | 15.3% | -1.6% | -0.6% | -2.2% |
| $337.9 | | $316.7 | | 6.7% | -0.4% | 6.3% | 5.9% | 7.8% | -1.0% | 6.8% |
| Domestic | $194.0 | | $183.2 | | 5.9% | 0.0% | 5.9% | | | | |
| International | 143.9 | | 133.5 | | 7.8% | -1.0% | 6.8% | | | | |
| $337.9 | | $316.7 | | 6.7% | -0.4% | 6.3% | | | | |
| Nine Months Ended September 30, |
|---|
| | | % Change |
|---|
| | | | | | Domestic | International |
|---|
| 2025 | 2024 | As Reported | Impact of Foreign Currency | Constant Currency | As Reported | As Reported | Impact of Foreign Currency | Constant Currency |
|---|
| Orthopedic Surgery | $417.2 | | $405.0 | | 3.0% | 0.3% | 3.3% | 0.8% | 4.4% | 0.5% | 4.9% |
| General Surgery | 584.3 | | 556.1 | | 5.1% | -0.1% | 5.0% | 5.7% | 3.6% | -0.1% | 3.5% |
| $1,001.5 | | $961.1 | | 4.2% | 0.1% | 4.3% | 4.3% | 4.1% | 0.2% | 4.3% |
| Single-use Products | $863.2 | | $814.8 | | 5.9% | 0.1% | 6.0% | 5.0% | 7.3% | 0.2% | 7.5% |
| Capital Products | 138.3 | | 146.3 | | -5.5% | 0.2% | -5.3% | -0.9% | -9.3% | 0.3% | -9.0% |
| $1,001.5 | | $961.1 | | 4.2% | 0.1% | 4.3% | 4.3% | 4.1% | 0.2% | 4.3% |
| Domestic | $568.3 | | $545.0 | | 4.3% | 0.0% | 4.3% | | | | |
| International | 433.2 | | 416.1 | | 4.1% | 0.2% | 4.3% | | | | |
| $1,001.5 | | $961.1 | | 4.2% | 0.1% | 4.3% | | | | |
| Gross Profit | Selling & Administrative Expense | Operating Income | Interest Expense | Other Expense | Tax Expense | Effective Tax Rate | Net Income | Diluted EPS |
|---|
| Reconciliation of Reported Net Income to Adjusted Net Income |
| (in thousands, except per share amounts, unaudited) |
| Three Months Ended September 30, 2025 |
| As reported | $166,119 | $140,339 | $11,879 | $7,606 | $- | $1,414 | 33.1% | $2,859 | $0.09 |
| % of sales | 49.2% | 41.5% | 3.5% | | | | | | |
| Product rationalization costs | 19,653 | - | 19,653 | - | - | 4,870 | | 14,783 | |
| Operational optimization consulting fees | 3,729 | (5,516) | 9,245 | - | - | 2,291 | | 6,954 | |
| Contingent consideration fair value adjustments | - | (1,341) | 1,341 | - | - | 332 | | 1,009 | |
| Legal matters | - | (319) | 319 | - | - | 79 | | 240 | |
| $189,501 | $133,163 | $42,437 | $7,606 | $- | $8,986 | | $25,845 | |
| Adjusted gross profit % | 56.1% | | | | | | | | |
| Amortization | $1,500 | (7,233) | 8,733 | (1,276) | - | 2,438 | | 7,571 | |
| As adjusted | | $125,930 | $51,170 | $6,330 | $- | $11,424 | 25.5% | $33,416 | $1.08 |
| % of sales | | 37.3% | 15.1% | | | | | | |
| Three Months Ended September 30, 2024 |
| Gross Profit | Selling & Administrative Expense | Operating Income | Interest Expense | Other Expense | Tax Expense | Effective Tax Rate | Net Income | Diluted EPS |
| As reported | $178,995 | $99,730 | $65,707 | $9,252 | $- | $7,471 | 13.2% | $48,984 | $1.57 |
| % of sales | 56.5% | 31.5% | 20.7% | | | | | | |
| Contingent consideration fair value adjustments | - | 27,049 | (27,049) | - | - | (1,319) | | (25,730) | |
| Legal matters | - | (1,885) | 1,885 | - | - | 92 | | 1,793 | |
| $178,995 | $124,894 | $40,543 | $9,252 | $- | $6,244 | | $25,047 | |
| Adjusted gross profit % | 56.5% | | | | | | | | |
| Amortization | $1,500 | (7,158) | 8,658 | (1,443) | - | 2,440 | | 7,661 | |
| As adjusted | | $117,736 | $49,201 | $7,809 | $- | $8,684 | 21.0% | $32,708 | $1.05 |
| % of sales | | 37.2% | 15.5% | | | | | | |
| (1) In 2025, the Company wrote off inventory, equipment, tooling and patents related to the cancellation of planned new product lines and discontinuation of certain catalog numbers as a result of our operational optimization consultation and internal review. |
| (2) In 2025, the Company incurred costs related to the engagement of a consulting firm to evaluate and propose improvements to our manufacturing operations which are included in cost of sales. In addition, we incurred consulting fees related to operational optimization which are included in selling & administrative expense. |
| (3) In 2025 and 2024, the Company recorded income/(expense) related to the fair value adjustments of contingent consideration. |
| (4) In 2025 and 2024, the Company incurred costs for third party services pertaining to potential issues with certain royalty payments to surgeons involved in design teams. |
| (5) Includes amortization of intangible assets and deferred financing fees. |
| Gross Profit | Selling & Administrative Expense | Operating Income | Interest Expense | Other Expense | Tax Expense | Effective Tax Rate | Net Income | Diluted EPS |
|---|
| Reconciliation of Reported Net Income to Adjusted Net Income |
| (in thousands, except per share amounts, unaudited) |
| Nine Months Ended September 30, 2025 |
| As reported | $532,190 | $425,207 | $65,998 | $23,716 | $418 | $11,548 | 27.6% | $30,316 | $0.97 |
| % of sales | 53.1% | 42.5% | 6.6% | | | | | | |
| Product rationalization costs | 19,653 | - | 19,653 | - | - | 4,870 | | 14,783 | |
| Operational optimization consulting fees | 12,262 | (8,456) | 20,718 | - | - | 4,045 | | 16,673 | |
| Executive transition costs | - | (12,165) | 12,165 | - | - | 2,812 | | 9,353 | |
| Legal matters | - | (2,548) | 2,548 | - | - | 453 | | 2,095 | |
| Contingent consideration fair value adjustments | - | (3,504) | 3,504 | - | - | 1,046 | | 2,458 | |
| Debt refinancing costs | - | - | - | - | (418) | 47 | | 371 | |
| Gain on sale of product line | - | 354 | (354) | - | - | (82) | | (272) | |
| $564,105 | $398,888 | $124,232 | $23,716 | $- | $24,739 | | $75,777 | |
| Adjusted gross profit % | 56.3% | | | | | | | | |
| Amortization | $4,500 | (21,597) | 26,097 | (4,107) | - | 7,335 | | 22,869 | |
| As adjusted | | $377,291 | $150,329 | $19,609 | $- | $32,074 | 24.5% | $98,646 | $3.17 |
| % of sales | | 37.7% | 15.0% | | | | | | |
| Nine Months Ended September 30, 2024 |
| Gross Profit | Selling & Administrative Expense | Operating Income | Interest Expense | Other Expense | Tax Expense | Effective Tax Rate | Net Income | Diluted EPS |
| As reported | $534,688 | $345,611 | $147,827 | $28,440 | $- | $20,719 | 17.4% | $98,668 | $3.17 |
| % of sales | 55.6% | 36.0% | 15.4% | | | | | | |
| Legal matters | - | (4,566) | 4,566 | - | - | 344 | | 4,222 | |
| Contingent consideration fair value adjustments | - | 42,267 | (42,267) | - | - | (2,650) | | (39,617) | |
| Restructuring and related costs | 235 | (1,539) | 1,774 | - | - | 255 | | 1,519 | |
| Asset impairment costs | 1,414 | - | 1,414 | - | - | 203 | | 1,211 | |
| Termination of distributor agreement | - | 970 | (970) | - | - | (139) | | (831) | |
| $536,337 | $382,743 | $112,344 | $28,440 | $- | $18,732 | | $65,172 | |
| Adjusted gross profit % | 55.8% | | | | | | | | |
| Amortization | $4,500 | (21,466) | 25,966 | (4,256) | - | 7,320 | | 22,902 | |
| As adjusted | | $361,277 | $138,310 | $24,184 | $- | $26,052 | 22.8% | $88,074 | $2.83 |
| % of sales | | 37.6% | 14.4% | | | | | | |
(1) In 2025, the Company wrote off inventory, equipment, tooling and patents related to the cancellation of planned new product lines and discontinuation of certain catalog numbers as a result of our operational optimization consultation and internal review.
(2) In 2025, the Company incurred costs related to the engagement of a consulting firm to evaluate and propose improvements to our manufacturing operations which are included in cost of sales. In addition, we incurred consulting fees related to operational optimization which are included in selling & administrative expense.
(3) In 2025, the Company incurred cash and stock-based compensation costs related to advisory services provided by our former Chief Executive Officer.
(4) In 2025 and 2024, the Company incurred costs for third party services pertaining to potential issues with certain royalty payments to surgeons involved in design teams.
(5) In 2025 and 2024, the Company recorded income/(expense) related to the fair value adjustments of contingent consideration.
(6) In 2025, the Company incurred costs related to a loss on early extinguishment and third-party fees associated with the eighth amended and restated senior credit agreement.
(7) In 2025, the Company recognized a gain on the sale of a product line.
(8) Includes amortization of intangible assets and deferred financing fees.
(9) In 2024, the Company incurred severance costs related to the elimination of certain positions.
(10) In 2024, the Company wrote off inventory, tooling and equipment related to the cancellation of a planned new product line.
(11) In 2024, the Company recorded an accrual adjustment related to the previous termination of a distributor agreement.
| Three Months Ended | Nine Months Ended |
|---|
| September 30, | September 30, |
|---|
| 2025 | 2024 | 2025 | 2024 |
|---|
| Reconciliation of Reported Net Income to EBITDA & Adjusted EBITDA |
| (in thousands, unaudited) |
| Net income | $2,859 | | $48,984 | | $30,316 | | $98,668 | |
| Provision for income taxes | 1,414 | | 7,471 | | 11,548 | | 20,719 | |
| Interest expense | 7,606 | | 9,252 | | 23,716 | | 28,440 | |
| Depreciation | 4,376 | | 4,195 | | 13,077 | | 12,406 | |
| Amortization | 14,231 | | 13,779 | | 42,354 | | 41,445 | |
| EBITDA | $30,486 | | $83,681 | | $121,011 | | $201,678 | |
| Stock based compensation | 4,585 | | 6,123 | | 15,869 | | 19,336 | |
| Product rationalization costs | 19,653 | | - | | 19,653 | | - | |
| Operational optimization consulting fees | 9,245 | | - | | 20,718 | | - | |
| Contingent consideration fair value adjustments | 1,341 | | (27,049) | | 3,504 | | (42,267) | |
| Legal matters | 319 | | 1,885 | | 2,548 | | 4,566 | |
| Debt refinancing costs | - | | - | | 418 | | - | |
| Executive transition costs | - | | - | | 12,165 | | - | |
| Gain on sale of product line | - | | - | | (354) | | - | |
| Restructuring and related costs | - | | - | | - | | 1,774 | |
| Asset impairment costs | - | | - | | - | | 1,414 | |
| Termination of distributor agreement | - | | - | | - | | (970) | |
| Adjusted EBITDA | $65,629 | | $64,640 | | $195,532 | | $185,531 | |
| EBITDA Margin | | | | |
| EBITDA | 9.0% | | 26.4% | | 12.1% | | 21.0% | |
| Adjusted EBITDA | 19.4% | | 20.4% | | 19.5% | | 19.3% | |
About CONMED Corporation
CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com.
Forward-Looking Statements
Forward-looking statements notice
This press release and associated conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2024, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.
Supplemental Information - Reconciliation of GAAP to Non-GAAP Financial Measures
The Company supplements the reporting of its financial information determined under generally accepted accounting principles in the United States (GAAP) with certain non-GAAP financial measures, including percentage sales growth in constant currency; adjusted gross profit; cost of sales excluding specified items; adjusted selling and administrative expenses; adjusted operating income; adjusted interest expense; adjusted other expense; adjusted income tax expense; adjusted effective income tax rate; adjusted net income and adjusted diluted net earnings per share (EPS). The Company believes that these non-GAAP measures provide meaningful information to assist investors and shareholders in understanding its financial results and assessing its prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of its operations because they exclude items that may not be indicative of, or are unrelated to, its core operating results and provide a baseline for analyzing trends in the Company’s underlying business. Further, the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company’s cash flow. Management uses these non-GAAP financial measures for reviewing the operating results and analyzing potential future business trends in connection with its budget process and bases certain management incentive compensation on these non-GAAP financial measures.
Net sales on a constant currency basis is a non-GAAP measure. The Company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. To measure percentage sales growth in constant currency, the Company removes the impact of changes in foreign currency exchange rates that affect the comparability and trend of net sales. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating trends.
Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, cost of sales, selling and administrative expenses, operating income, interest expense, other expense, income tax expense, effective income tax rate, net income and diluted net earnings per share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures above, provide a more complete understanding of the business. The Company strongly encourages investors and shareholders to review its financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.
We are unable to present a quantitative reconciliation of our expected diluted net earnings per share to expected adjusted diluted net earnings per share as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of acquisition, integration and other charges. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our consolidated condensed statements of income.
Contacts
CONMED Corporation
Todd W. Garner
Chief Financial Officer
ToddGarner@conmed.com